Leadership

Mitchell H. Finer, Ph.D.
Chief Executive Officer

Mitchell H. Finer, Ph.D. - Chief Executive Officer at Oncorus

Mitchell H. Finer, Ph.D.

Chief Executive Officer

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D. - Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.

Chief Scientific Officer

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology

Lorena Lerner, Ph.D.

Senior Director, Molecular Biology

Michael Paglia
Vice President, CMC Operations

Michael Paglia, Vice President, CMC Operations at Oncorus

Michael Paglia

Vice President, CMC Operations

Eric M. Sullivan, CPA
Senior Vice President, Finance & Operations, Treasurer

Eric M. Sullivan, CPA - Senior Vice President, Finance & Operations, Treasurer at Oncorus

Eric M. Sullivan, CPA

Senior Vice President, Finance & Operations, Treasurer

Mitch H. Finer Ph.D., Chief Executive Officer at Oncorus

Mitchell H. Finer, Ph.D.
Chief Executive Officer

Mitchell H. Finer, PhD founded Oncorus and currently serves as Chief Executive Officer and “Chief Coolhunter”. As CEO, he has responsibility for guiding the strategic build of Oncorus and overseeing operations across the company. As Chief Coolhunter, Dr. Finer is ever on the prowl for innovative technologies that will increase the probability of success of existing development programs as well as product opportunities that are synergistic with the existing portfolio and will overall improve the success of the business.

Mitch joined MPM Capital as Managing Director in 2015 and is a member of the board of directors of MPM portfolio company Semma Therapeutics. For three decades Mitch has focused in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, helping to advance products from conception through phase III clinical programs. Prior to MPM, Mitch served as CSO of bluebird bio, where he was responsible for strategic build of bluebird’s gene therapy business and led the strategic development of the LentiGlobin product from preclinical research through demonstration of long-term therapeutic benefit and safety in beta-thalassemia patients. Mitch continues to serve on bluebird bio’s scientific advisory board.

Prior to bluebird, Mitch served as CEO of Intracel Corporation and Genteric Inc, and as VP Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi). Mitch also successfully co-founded retinal disease gene therapy company Avalanche Biotechnologies.

Mitch received his PhD in Biochemistry and Molecular Biology from Harvard University and a BS in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at MIT.

Christophe Quéva, Ph.D. Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval.

Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.

A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Eric M. Sullivan, CPA Senior Vice President, Finance & Operations, Treasurer at Oncorus

Eric M. Sullivan, CPA
Senior Vice President, Finance & Operations, Treasurer

Eric M. Sullivan serves as Senior Vice President, Finance & Operations and Treasurer, responsible for finance and accounting, administration and corporate operations. Eric is passionate about helping to bring truly innovative therapies to patients.

Prior to joining Oncorus, Eric spent 4 years at bluebird bio, Inc. where he served as Vice President, Finance, Treasurer and Principal Accounting Officer. At bluebird Eric helped raise over $1.5 billion through multiple public equity financings and helped build and scale the finance team during a period of tremendous company growth. Prior to bluebird, Eric spent 5 years at Merrimack Pharmaceuticals as Corporate Controller. At Merrimack Eric helped prepare and execute an IPO, acquisition and major collaboration. Eric started his career at PricewaterhouseCoopers where he spent 6 years as a Manager in the assurance practice. Eric received his B.S. in accountancy from Bentley College and is a Certified Public Accountant in Massachusetts.

Michael Paglia, Vice President, CMC Operations at Oncorus

Michael Paglia
Vice President, CMC Operations

The Oncorus Chemistry, Manufacturing and Controls department consisting of process development, manufacturing, analytical sciences and quality control is led by Michael. Michael has spent the last fifteen years in biotechnology building and leading process development and manufacturing teams to support clinical programs from early development to late stage clinical trials.

Most recently, Michael was the Sr. Director of Technical Operations and head of Cellular Process Development and Manufacturing Operations at bluebird bio. Michael established and was responsible for internal and external cellular process development and analytics, cGMP manufacturing operations, CMC regulatory strategy, cellular procurement, and process characterization and validation activities. For over four years, Michael and his team successfully completed the development, scale-up, characterization, technology transfer and manufacturing of drug product for all lentiviral vector-based autologous hematopoietic stem cell and CAR T cell programs.

Prior to joining bluebird bio, Michael was the Director of Manufacturing and head of Process Development at Tolerx, Inc. where he was responsible for advancing multiple immunology and cancer biology programs from discovery to late stage clinical manufacturing including the Phase III/commercial candidate Otelixizumab.

Michael received a BS in Biology from Providence College and a MSc in Biochemistry and Molecular Biology from the University of New Hampshire.

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology at Oncorus

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner Ph.D. is the Senior Director of Molecular Biology at Oncorus, where she is leading the efforts to engineer more potent and safer novel armed oncolytic viral vectors for the treatment of solid tumors.

Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery into clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for leading the development of proprietary nanotechnology platform, identifying potent immunotherapy target candidates and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation and antibody discovery through preclinical development and out-licensing enterprises.

Lorena received an MSc in Molecular Biology and a PhD in Biochemistry from University of Buenos Aires. She completed post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused in the field of gene regulation and cancer molecular biology. Lorena is a co-inventor of numerous patents and high-impact, peer-reviewed manuscripts and abstracts.